A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 20, Issue 2-3, 2005, Pages 178-183

  Jessen, Frank ^a   Traeber, Frank ^a   Freymann, Nikolaus ^a   Maier, Wolfgang ^a   Schild, Hans H ^a   Heun, Reinhard ^a   Block, Wolfgang ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer's disease; Medial temporal lobe; N acetylaspartate; Proton magnetic resonance spectroscopy

Indexed keywords

CREATINE; N ACETYLASPARTIC ACID;

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BIOCHEMISTRY; BRAIN METABOLISM; BRAIN SIZE; BRAIN WATER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPORAL LOBE;

AGED; ALZHEIMER DISEASE; ASPARTIC ACID; CHOLINE; CREATINE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; TEMPORAL LOBE;

EID: 23944432134     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087095     Document Type: Article

References (22)

1. Valenzuela MJ, Sachdev P: Magnetic resonance spectroscopy in AD. Neurology 2001; 56:592-598.
2. Cheng LL, Newell K, Mallory AE, Hyman BT, Gonzalez RG: Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn Reson Imaging 2002;20:527-533.
3. Block W, Traber F, Kuhl CK, Fric M, Keller E, Lamerichs R, Rink H, Moller HJ, Schild HH: 1H-MR spectroscopic imaging in patients with clinically diagnosed Alzheimer's disease. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995;163:230-237.
4. Block W, Jessen F, Traber F, Flacke S, Manka C, Lamerichs R, Keller E, Heun R, Schild HH: Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch Neurol 2002;59:828-834.
5. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD: Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 2002; 125:2332-2341.
6. Engelhardt E, Moreira DM, Laks J, Marinho VM, Rozenthal M, Oliveira AC: Alzheimer's disease and magnetic resonance spectroscopy of the hippocampus. Arq Neuropsiquiatr 2001; 59:865-870.
7. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, Lamerichs R, Heun R, Schild HH: Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000;55:684-688.
8. Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, Schild HH, Heun R: Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001;57:930-932.
9. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH, Mastrianni JA, Fein G, Weiner MW: Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997;49:1513-1521.
10. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D, Kramer J, Jagust W, Miller B, Wolkowitz OM, Yaffe K, Weiner MW: Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002;58:928-935.
11. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO: In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry 1999;56:185-192.
12. Bottomley PA: Spatial localization in NMR spectroscopy. Ann NY Acad Sci 1987;508:333-348.
13. Shen JF, Saunders JK: Double inversion recovery improves water suppression in vivo. Magn Reson Med 1993;29:540-542.
14. Gredal O, Rosenbaum S, Topp S, Karlsborg MS, Werdelin L: Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997;48:878-881.
15. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group: Consensus report of the Working Group on: 'Molecular and biochemical markers of Alzheimer's Disease'. Neurobiol Aging 1998;19: 106-116.
16. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003;160: 2003-2011.
17. Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, Boeve BF, Edland SD, Kokmen E, Tangalos EG, Petersen RC, Jack CR Jr: Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:198-207.
18. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD: Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995;195:65-72.
19. Chao LL, Schuff N, Kramer JH, Du AT, Capizzano AA, O'Neill J, Wolkowitz OM, Jagust WJ, Chui HC, Miller BL, Yaffe K, Weiner MW: Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but non-demented patients. Neurology 2005;64:282-289.
20. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR Jr: 1H MR spectroscopy in common dementias. Neurology 2004; 63:1393-1398.
21. Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y: Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004;1003:26-35.
22. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D, Jagust WJ, Chui HC, Kramer JH, Reed BR, Miller BL, Yaffe K, Weiner MW: Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology 2003;61:358-364.